References
- Bento L, Diaz-Lopez A, Barranco G, et al. New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO). Br J Haematol. 2020;188(6):888–897.
- Gleeson M, Hawkes EA, Cunningham D, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial. Br J Haematol. 2016;175(4):668–672.
- Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379–391.
- Sekijima T, Tanabe A, Maruoka R, et al. Impact of platinum-based chemotherapy on the progression of atherosclerosis. Climacteric. 2011;14(1):31–40.
- Nuver J, Smit AJ, Sleijfer DT, et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer. 2004;40(5):701–706.
- Horvath B, Hegedus D, Szapary L, et al. Measurement of von Willebrand factor as the marker of endothelial dysfunction in vascular diseases. Exp Clin Cardiol. 2004;9(1):31–34.
- Menih M, Krizmaric M, Hojs Fabjan T. Clinical role of von Willebrand factor in acute ischemic stroke. Wien Klin Wochenschr. 2017;129(13–14):491–496.
- Wieberdink RG, van Schie MC, Koudstaal PJ, et al. High von Willebrand factor levels increase the risk of stroke: the rotterdam study. Stroke. 2010;41(10):2151–2156.
- Gragnano F, Sperlongano S, Golia E, et al. The role of von willebrand factor in vascular inflammation: from pathogenesis to targeted therapy. Mediators Inflamm. 2017;2017:5620314.
- Fujioka I, Takaku T, Iriyama N, et al. Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database. Ann Hematol. 2018;97(11):2081–2088.
- Kalabova H, Melichar B, Ungermann L, et al. Intima-media thickness, myocardial perfusion and laboratory risk factors of atherosclerosis in patients with breast cancer treated with anthracycline-based chemotherapy. Med Oncol. 2011;28(4):1281–1287.
- Sahebkar A, Serban C, Ursoniu S, et al. The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and Meta-analysis of randomised placebo-controlled trials. Thromb Haemost. 2016;115(3):520–532.
- Kiechl S, Willeit J. The natural course of atherosclerosis. Part I: incidence and progression. Arterioscler Thromb Vasc Biol. 1999;19(6):1484–1490.
- Tran LT, Park HJ, Kim HD. Is the carotid intima-media thickness really a good surrogate marker of atherosclerosis? JAT. 2012;19(7):680–690.
- Zhang J, Zhao WS, Xu L, et al. Endothelium-specific endothelin-1 expression promotes pro-inflammatory macrophage activation by regulating miR-33/NR4A axis. Exp Cell Res. 2021;399(1):112443.
- Dakhel A, Engstrom G, Melander O, et al. Vasoactive biomarkers associated with long-term incidence of symptomatic peripheral arterial disease and mortality. Angiology. 2021;72(6):550–555.